Published in Arthritis Rheum on June 01, 2009
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis (2016) 1.41
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis Rheumatol (2016) 1.40
A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) (2010) 1.29
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 1.27
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol (2009) 1.27
Myositis autoantibodies. Curr Opin Rheumatol (2012) 1.25
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am (2013) 1.18
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther (2011) 1.14
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.10
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther (2013) 1.04
Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle (2013) 1.03
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther (2012) 0.97
Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (2015) 0.94
Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther (2011) 0.92
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep (2014) 0.89
Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis (2013) 0.85
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) (2014) 0.85
Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol (2014) 0.85
Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol (2016) 0.81
Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis (2012) 0.81
Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials (2015) 0.79
Myeloperoxidase-antineutrophil cytoplasmic antibody-related crescentic glomerulonephritis after treatment for clinically amyopathic dermatomyositis: a coincidental combination or not? Clin Exp Nephrol (2011) 0.79
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med (2016) 0.78
PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. Ann Rheum Dis (2015) 0.78
Morc3 mutant mice exhibit reduced cortical area and thickness, accompanied by altered haematopoietic stem cells niche and bone cell differentiation. Sci Rep (2016) 0.75
Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase. Cell Rep (2016) 0.75
Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol (2014) 0.75
Treatment of Juvenile Dermatomyositis: An Update. Paediatr Drugs (2017) 0.75
[New aspects on the pathogenesis of myositis]. Z Rheumatol (2013) 0.75
Dermatomyositis Patients with Anti-Nuclear Matrix Protein-2 Autoantibodies Have More Edema, More Severe Muscle Disease, and Increased Malignancy Risk. Arthritis Care Res (Hoboken) (2017) 0.75
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
Polymyositis and dermatomyositis (second of two parts). N Engl J Med (1975) 7.26
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) (1991) 4.01
Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum (1994) 3.52
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum (2003) 2.21
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum (2000) 1.91
TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum (2000) 1.71
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol (2002) 1.62
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci U S A (2006) 1.59
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) (2008) 1.44
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 1.37
Myositis specific autoantibodies. Curr Rheumatol Rep (2006) 1.29
The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol (1995) 1.27
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity (2006) 1.27
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) (2006) 1.25
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum (2006) 1.23
Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol (2000) 1.16
Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am (2002) 1.12
Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) (2007) 1.10
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) (2007) 1.08
Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum (2007) 1.04
HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids. Hum Immunol (1992) 1.03
Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene (2004) 1.00
The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem (2002) 0.99
A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum (1994) 0.94
Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol (2008) 0.93
Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol (1996) 0.89
Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs (2005) 0.89
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12
Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (1992) 3.80
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Normal muscle strength and fatigability in patients with effort syndromes. BMJ (1988) 2.46
Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. J Pharmacol Exp Ther (1971) 2.34
Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol (2013) 2.11
Bullous pemphigoid following radiotherapy. Clin Exp Dermatol (1995) 2.03
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol (1992) 1.85
Plesiomonas shigelloides in South Australia. J Clin Pathol (1968) 1.80
Review of haemophagocytic lymphohistiocytosis. Arch Dis Child (2010) 1.80
Perception of numbers by human infants. Science (1980) 1.77
Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child (2005) 1.74
Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol (1990) 1.74
Adjuvant chemotherapy of breast cancer. Cancer (1979) 1.73
An RGD-oligolysine peptide: a prototype construct for integrin-mediated gene delivery. Hum Gene Ther (1998) 1.73
Keloid disease: clinical relevance of single versus multiple site scars. Br J Plast Surg (2005) 1.62
Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford) (2008) 1.60
Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol (1994) 1.57
Systemic lupus erythematosus complicating hyper IgE syndrome. Br J Rheumatol (1997) 1.55
Systemic juvenile idiopathic arthritis, Kikuchi's disease and haemophagocytic lymphohistiocytosis--is there a link? Case report and literature review. Rheumatology (Oxford) (2003) 1.55
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) (2006) 1.49
Characterisation of anticytoplasmic antibodies and their clinical associations. Ann Rheum Dis (1995) 1.46
Migraine and migrainous stroke: risk factors and prognosis. Neurology (1993) 1.46
Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India. Indian Pediatr (2010) 1.45
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) (2008) 1.44
What is pain management, and what is its relevance to the rheumatologist? Rheumatology (Oxford) (2003) 1.40
Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) (2002) 1.39
Atypical antineutrophil cytoplasmic antibodies in patients with ankylosing spondylitis. Br J Rheumatol (1995) 1.38
Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol (1997) 1.37
Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) (2004) 1.32
Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum (2005) 1.31
Iodometric detection of staphylococcal penicillinase in clinical microbiology. Aust J Exp Biol Med Sci (1966) 1.27
Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study. Hum Mol Genet (2006) 1.27
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) (2006) 1.25
Muscle fibre size and type distribution in thoracic and lumbar regions of erector spinae in healthy subjects without low back pain: normal values and sex differences. J Anat (1997) 1.22
Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood (2000) 1.16
Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol (1997) 1.16
Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Ann Rheum Dis (2007) 1.16
HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol (1993) 1.15
Juvenile chronic arthritis. Lancet (1998) 1.14
Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum (1997) 1.14
Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest (1991) 1.13
CD34(+)/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am J Respir Cell Mol Biol (1999) 1.12
Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol (1993) 1.12
Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet (1984) 1.11
Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol (1997) 1.10
Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) (2007) 1.10
Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. Ann Rheum Dis (1996) 1.09
Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus. Tissue Antigens (2006) 1.09
Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol (1995) 1.09
Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) (2008) 1.08
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) (2007) 1.08
EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int J Epidemiol (2008) 1.08
Cathepsin D exon 2 polymorphism associated with general intelligence in a healthy older population. Mol Psychiatry (2003) 1.08
Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) (2008) 1.07
Canine DLA diversity: 1. New alleles and haplotypes. Tissue Antigens (2007) 1.07
Nitrous oxide analgesia during intra-articular injection for juvenile idiopathic arthritis. Arch Dis Child (2002) 1.07
Psoriatic arthritis: clinical subgroups and histocompatibility antigens. Ann Rheum Dis (1987) 1.06
Mitochondrial ATP synthase F1-beta-subunit is a calcium-binding protein. FEBS Lett (1996) 1.06
Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum (2007) 1.05
Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford) (2004) 1.05
Subfamilies of CR1 non-LTR retrotransposons have different 5'UTR sequences but are otherwise conserved. Gene (2001) 1.05
Extensive interbreed, but minimal intrabreed, variation of DLA class II alleles and haplotypes in dogs. Tissue Antigens (2002) 1.04
European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis (2001) 1.04
Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child (2003) 1.03
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum (2008) 1.02
Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol (2000) 1.02
Polymorphism in the STAT6 gene encodes risk for nut allergy. Genes Immun (2002) 1.02
Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol (1989) 1.01
Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology (2006) 1.01
Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet (1999) 1.00
Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. J Allergy Clin Immunol (1994) 1.00
Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population. Brain (2004) 1.00
Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken) (2012) 1.00
Isolation of ERp29, a novel endoplasmic reticulum protein, from rat enamel cells. Evidence for a unique role in secretory-protein synthesis. Eur J Biochem (2000) 0.99
Secondary Cushing's syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration. Rheumatology (Oxford) (2005) 0.98
Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) (2004) 0.98
Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J Immunol (1998) 0.98
Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. Blood (2000) 0.98
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis (2004) 0.98